CEACAM5 and adenocarcinoma: Several serological markers (e.g., carcinoembryonic antigen [CEA] for adenocarcinoma and cytokeratin 19 fragment [CYFRA] for squamous cell carcinoma) have been used clinically for diagnostic and prognostic prediction and monitoring disease progression, recurrence, and response to treatment2.